Novel platelet storage conditions: Additive solutions, gas, and cold

Current Opinion in Hematology

Volumn 21, Issue 6, 2014, Pages 491-496

  Capocelli, Kelley E ^a   Dumont, Larry J ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cold storage; Cryopreservation; Pathogen reduction; Platelet additive solution; Platelets

Indexed keywords

XENON; GAS; SOLUTION AND SOLUBILITY;

BLOOD TRANSFUSION REACTION; COLD EXPOSURE; CRYOPRESERVATION; GAS; HUMAN; NONHUMAN; PLATELET ADDITIVE SOLUTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REFRIGERATOR; REVIEW; ROOM TEMPERATURE; SHELF LIFE; SOLUTION AND SOLUBILITY; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; WARMING; BLOOD STORAGE; COLD; PROCEDURES; THROMBOCYTE;

BLOOD PLATELETS; BLOOD PRESERVATION; COLD TEMPERATURE; GASES; HUMANS; PLATELET TRANSFUSION; SOLUTIONS;

EID: 84927586030     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000081     Document Type: Review

References (47)

1. Heaton WA. Costs and benefits of PAS platelets: a mix of science, quality, and value. Transfusion 2013; 53:2597-2602.
2. Tobian AA, Fuller AK, Uglik K, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment. Transfusion 2014; 54:1523-1529.
3. Cohn CS, Stubbs J, Schwartz J, et al.A comparison of adverse reaction rates for PASC versus plasma platelet units. Transfusion 2014. [Epub ahead of print]
4. Surowiecka M, Zantek N, Morgan S, et al. Anti-A and anti-B titers in group O platelet units are reduced in PAS C versus conventional plasma units. Transfusion 2014; 54:255-256.
5. Rock GA, Adams GA. Plasma-free medium for platelet storage. US 4123856; 14 December 1982.
6. Nogawa M, Naito Y, Chatani M, et al. Parallel comparison of apheresiscollected platelet concentrates stored in four different additive solutions. Vox Sang 2013; 105:305-312.
7. Nguyen KA, Chavarin P, Arthaud CA, et al. Do manual and automated processes with distinct additive solutions affect whole blood-derived platelet components differently? Blood Transfus 2013; 11:152-153.
8. Saunders C, Rowe G, Wilkins K, Collins P. Impact of glucose and acetate on the characteristics of the platelet storage lesion in platelets suspended in additive solutions with minimal plasma. Vox Sang 2013; 105:1-10.
9. Radwanski K, Wagner SJ, Skripchenko A, Min K. In vitro variables of apheresis platelets are stably maintained for 7 days with 5% residual plasma in a glucose and bicarbonate salt solution, PAS-5. Transfusion 2012; 52:188-194.
10. Radwanski K, Min K. The role of bicarbonate in platelet additive solution for apheresis platelet concentrates stored with low residual plasma. Transfusion 2013; 53:591-599.
11. Skripchenko A, Turgeon A, Thompson-Montgomery D, et al. Evaluation of in vitro storage properties of apheresis platelets suspended in a bicarbonatecontaining additive solution with low levels of plasma and stored with a 24-h interruption of agitation. Vox Sang 2014; 106:337-343.
12. Dumont LJ, Cancelas JA, Graminske S, et al. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion 2013; 53:972-980.
13. Vassallo RR, Adamson JW, Gottschall JL, et al. In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma. Transfusion 2010; 50:2376-2385.
14. Slichter SJ, Corson J, Jones MK, et al. Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS). Blood 2014; 123:271-280.
15. Dumont LJ, Dumont DF, Unger ZM, et al. A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7-day-stored PLT-rich plasma and buffy coat PLTs from the same subjects. Transfusion 2011; 51:1241-1248.
16. Slichter SJ, Bolgiano D, Corson J, et al. Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution. Transfusion 2014. [Epub ahead of print]
17. Greco CA, Zhang JG, Kalab M, et al. Effect of platelet additive solution on bacterial dynamics and their influence on platelet quality in stored platelet concentrates. Transfusion 2010; 50:2344-2352.
18. Dumont LJ, Wood TA, Housman M, et al. Bacterial growth kinetics in ACD-A apheresis platelets: comparison of plasma and PAS III storage. Transfusion 2011; 51:1079-1085.
19. Van der Meer PF, Kerkhoffs JL, Curvers J, et al. In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system. Vox Sang 2010; 98:517-524.
20. Kerkhoffs JL, van Putten WL, Novotny VM, et al. Dutch-Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150:209-217.
21. Picker SM, Tauszig ME, Gathof BS. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion 2012; 52:510-516.
22. Galan AM, Lozano M, Molina P, et al. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 2011; 51:808-815.
23. Johnson L, Winter KM, Reid S, et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101:208-214.
24. Reid S, Johnson L, Woodland N, Marks DC. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion 2012; 52:2094-2103.
25. Castrillo A, Cardoso M, Rouse L. Treatment of buffy coat platelets in platelet additive solution with the mirasol(1) pathogen reduction technology system. Transfus Med Hemother 2013; 40:44-48.
26. Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability: deleterious effect of refrigerated storage. N Eng J Med 1969; 280:1094-1098.
27. Van der Wal DE, Gitz E, Du VX, et al. Arachidonic acid depletion extends survival of cold-stored platelets by interfering with the [glycoprotein Iba-14-3-3z] association. Haematologica 2012; 97:1514-1522.
28. Jansen AJ, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIba metalloproteinasemediated cleavage in mice. Blood 2012; 119:1263-1273.
29. Cap AP, Montgomery R, Pidcoke HF, et al. Functionality of chilled platelets stored under hyperbaric xenon. Transfusion 2013; 53:80A.
30. McGill M. Temperature cycling preserves platelet shape and enhances in vitro test scores during storage at 48C. J Lab Clin Med 1978; 92:971-972.
31. Xu F, Gelderman MP, Farrell J, Vostal JG. Temperature cycling improves in vivo recovery of cold-stored human platelets in a mouse model of transfusion. Transfusion 2013; 53:1178-1186.
32. Montgomery RK, Reddoch KM, Evani SJ, et al. Enhanced shear-induced platelet aggregation due to low-temperature storage. Transfusion 2013; 53: 1520-1530.
33. Pidcoke HF, Spinella PC, Ramasubramanian AK, et al. Refrigerated platelets for the treatment of acute bleeding: a review of the literature and reexamination of current standards. Shock 2014; 41:51-53. (Suppl 1).
34. Reddoch KM, Picoke HF, Montgomery RK, et al. Hemostatic function of apheresis platelets stored at 48C and 228C. Shock 2014; 41 (Suppl 1):54-61.
35. Valeri CR, Feingold H, Marchionni LD. A simple method for freezing human platelets using 6per cent dimethylsulfoxide and storage at-80 degrees C. Blood 1974; 43:131-136.
36. Valeri CR. Hemostatic effectiveness of liquid-preserved and previously frozen human platelets. N Engl J Med 1974; 290:353-358.
37. Khuri SF, Healey N, MacGregor H, et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 117:172-183.
38. Valeri CR, Ragno G, Khuri S. Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at-80 degrees C without postthaw processing. Transfusion 2005; 45:1890-1898.
39. Shiffer CA, Aisner J, Dutcher JP. Platelet cryopreservation using dimethyl sufloxide. Ann NY Acad Sci 1983; 411:161-169.
40. Johnson L, Coorey CP, Marks DC. The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles. Transfusion 2014. [Epub ahead of print]
41. Dumont LJ, Cancelas JA, Dumont DF, et al. A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide-frozen autologous platelets in healthy volunteers. Transfusion 2013; 53:128-137.
42. Provisions relating to apheresis platelets concentrates, the conditions and durations of storage [in French]. Journal officiel de La République Française 2010. www.journal-officiel.gouv.fr. [Accessed 4 May 2014]
43. Dumont LJ, Slichter SJ, Reade MC. Cryopreserved platelets: frozen in a logjam? Transfusion 2014. [In press]
44. Council of Europe. Platelets components. In: Keitel S, editor. Guide to the preparation, use and quality assurance of blood components. 17th ed. Strasbourg: Council of Europe Publishing; 2013346-350.
45. Lelkens CCM, Koning JG, de Kort B, et al. Experiences with frozen blood products in the Netherlands military. Transfus Apher Sci 2006; 34:289-298.
46. Neuhaus SJ, Wishaw K, Lelkens C. Australian experience with frozen blood products on military operations. Med J Aust 2010; 15:203-205.
47. Noorman F, Badloe JF. Efficient logistics available, compatible, safe and effective in the treatment of trauma patients with or without massive blood loss in military theatre. Transfusion 2012; 52 (S3):S53-030H.